Among the FDA‐approved urine‐based biomarker assays for bladder cancer detection and surveillance, including the Bladder Tumor Antigen (BTA) test, Nuclear Matrix Protein 22 (NMP22) test, and UroVysion test, the reported diagnostic performance remains suboptimal, with an overall sensitivity of 57%–82% and a negative predictive value (NPV) of 21%–48% [9, 10]. This evidence concerns the gene NUMA1 and urinary bladder carcinoma.